secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-059763
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q3 2023 net loss narrows to $8.1M; cash runway through 2025
--------------------------------------------------------------------------------

- Q3 2023 revenue $13.1M (up from $7.4M YoY); net loss $8.1M ($0.07/share) vs $23.9M ($0.22/share) in Q3 2022.
- Cash and equivalents $122.2M; expects runway through end of 2025, sufficient for Phase 1 data for lead in vivo programs.
- Completed Imugene deal for azer-cel: $21M upfront plus potential $198M milestones and double-digit royalties.
- PBGENE-HBV targeting CTA/IND in 2024; PBGENE-PMM targeting 2025; iECURE-OTC CTA/IND expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023059763/0000950170-23-059763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023059763/dtil-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer